Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has shared an update.
Pharmaron Beijing Co., Ltd. announced its estimated annual results for 2024, projecting an increase in revenue and net profit attributable to owners of the parent, with revenue expected to grow by 4% to 7% and net profit by 8% to 16% compared to the previous year. However, the company anticipates a decrease in net profit excluding non-recurring gains or losses and non-IFRSs adjusted net profit, due to factors such as the disposal of equity interests in PROTEOLOGIX and other financial movements. These results reflect strategic decisions impacting the company’s financials and demonstrate a mixed performance outlook that stakeholders should consider.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical and biotechnology industry. The company, along with its subsidiaries, is involved in providing comprehensive services across the drug discovery and development process, focusing on areas such as drug research, development, and manufacturing.
YTD Price Performance: 0.58%
Average Trading Volume: 157
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €5.58B
See more data about 3759 stock on TipRanks’ Stock Analysis page.